Share this Post

TearScience was acquired by Johnson & Johnson (NYSE: JNJ) in September 2017.

Headquartered in Morrisville, North Carolina, TearScience has pioneered diagnostic and treatment devices for evaporative dry eye, providing significant clinical improvement. Of the more than 100 million dry eye sufferers worldwide, approximately 70 percent have evaporative dry eye caused by lipid deficiency of the eye’s natural tear film. TearScience’s integrated, in-office system is the first to enable eye care professionals to address the root cause of evaporative dry eye.

General Catalyst Team